Lixisenatide Acetate
Synthetic glucagon like peptide 1 receptor agonist peptide
Research material. Not for human or animal consumption.
Research overview
Lixisenatide acetate is the salt form in which lixisenatide is usually manufactured and supplied. The GetGoal Phase 3 programme studied it in type 2 diabetes, especially added to basal insulin and metformin, where its strong effect on after-meal glucose complemented insulin's effect on fasting glucose. That pairing led to iGlarLixi (Soliqua/Suliqua), a fixed combination with insulin glargine. For analytical work, the acetate counterion means gross powder weight is not the same as peptide content.
An authorisation applies to at least one defined finished product in a stated jurisdiction; it does not apply automatically to this catalogue material.
Questions about Lixisenatide Acetate
PRODUCT QUESTIONSWhat is Lixisenatide Acetate?
Lixisenatide Acetate is lixisenatide supplied with acetate as the counterion. The peptide part is a 44 residue exendin 4 analogue; acetate and water account for part of the solid's weight.
What research has been published on Lixisenatide Acetate?
The GetGoal studies compared lixisenatide with placebo and other drugs when added to metformin, sulfonylureas or basal insulin, measuring HbA1c, mealtime glucose, weight and nausea. Combination trials with insulin glargine supported the fixed ratio product. Results apply to defined clinical products rather than research material.
What batch documentation should accompany Lixisenatide Acetate?
Lixisenatide Acetate: Ask for the COA and analytical reports for the batch being quoted. The key figure for this salt form is peptide content, so ask for acetate and water content alongside mass spectrometry and HPLC purity.
How should Lixisenatide Acetate storage conditions be assessed?
Store Lixisenatide Acetate refrigerated at 2°C to 8°C before opening, protected from light. Acetate salts absorb moisture, so let vials reach room temperature before opening to avoid condensation.